Camber Pharmaceuticals Launches Generic Lamictal XR
Camber Pharmaceuticals is pleased to announce the addition of Lamotrigine ER Tablets to its current portfolio.
Lamotrigine ER Tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial- onset seizures with or without secondary generalization in patients aged 13 years and older.
Lamotrigine ER Tablets from Camber are available in 25, 50, 100, 200, 250, and 300 mg strengths in 30 count bottles.
To find out more about Lamotrigine ER Tablets please visit
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
SOURCE: Camber Pharmaceuticals
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- NCPA Announces Keynote Speaker for Annual Convention
September 18th 2025
- Upcoming NCPA Items for Pharmacy Teams: September and October 2025
September 11th 2025
- NCPA Applauds FTC Pick for Associate Director of Health Care
September 10th 2025
- NCPA Leads Huge Coalition in Letter Asking Congress to Pass PBM Reform Act
September 8th 2025